Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$84.6 million.

  • Viridian Therapeutics, Inc.\DE's Cash from Operations fell 2496.82% to -$84.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$326.0 million, marking a year-over-year decrease of 6547.74%. This contributed to the annual value of -$232.3 million for FY2024, which is 2614.38% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Cash from Operations stood at -$84.6 million for Q3 2025, which was down 2496.82% from -$75.4 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Cash from Operations registered a high of -$11.5 million during Q1 2021, and its lowest value of -$92.7 million during Q1 2025.
  • Its 5-year average for Cash from Operations is -$43.0 million, with a median of -$39.0 million in 2023.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Cash from Operations plummeted by 19452.05% in 2023 and then surged by 2702.79% in 2024.
  • Viridian Therapeutics, Inc.\DE's Cash from Operations (Quarter) stood at -$16.5 million in 2021, then plummeted by 105.88% to -$34.0 million in 2022, then decreased by 11.63% to -$38.0 million in 2023, then crashed by 92.98% to -$73.3 million in 2024, then fell by 15.38% to -$84.6 million in 2025.
  • Its Cash from Operations stands at -$84.6 million for Q3 2025, versus -$75.4 million for Q2 2025 and -$92.7 million for Q1 2025.